A US District Court for the District of Delaware ordered Guardant Health to pay roughly $245 million in damages, royalties, and interest to TwinStrand Biosciences and the University of Washington over duplex sequencing patents. The court’s ruling includes supplemental damages on top of an earlier $83.4 million damages finding from a 2023 decision. The judgment also calls for an ongoing 6% royalty rate tied to 11 products and requires quarterly US sales accounting for the covered assays and services, including Guardant360 and related LUNAR-1 testing. TwinStrand and UW originally sued in 2021 alleging willful infringement. While Guardant has indicated it is preparing an appeal and continues to challenge patent validity through PTAB, the decision reinforces IP leverage around duplex consensus sequencing—an approach central to lowering sequencing error rates in clinical genomics.